{"id":"high-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":{"setId":"03f2c9fc-534b-49ec-9113-81938b1eadb9","title":"FLUZONE HIGH-DOSE QUADRIVALENT NORTHERN HEMISPHERE (INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/CROATIA/10136RV/2023 X-425A (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (FORMALDEHYDE INACTIVATED), AND INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACTIVATED)) INJECTION, SUSPENSION [SANOFI PASTEUR INC.]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of high-dose treatment can vary depending on the medication and the condition being treated. However, the general principle is to use a higher dose to achieve a more pronounced effect, which can be beneficial for patients who do not respond well to standard doses.","oneSentence":"High-dose treatment involves administering a higher-than-standard dose of a medication to achieve a specific therapeutic effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:41:49.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various conditions"}]},"trialDetails":[{"nctId":"NCT03654105","phase":"PHASE2","title":"Screening and Multiple Intervention on Lung Epidemics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2019-07-23","conditions":"Inflammation, Smoking Cessation, Diet Modification","enrollment":2000},{"nctId":"NCT07161011","phase":"PHASE2","title":"Phase 2b Controlled Study of Dosing Techniques - Part B","status":"COMPLETED","sponsor":"IVIEW Therapeutics Inc.","startDate":"2025-09-08","conditions":"Dry Eye","enrollment":15},{"nctId":"NCT05768932","phase":"PHASE1","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2022-12-14","conditions":"Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer","enrollment":260},{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases","enrollment":354},{"nctId":"NCT06417853","phase":"PHASE1","title":"Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)","status":"COMPLETED","sponsor":"Vaxxas Pty Ltd","startDate":"2024-07-31","conditions":"H7N9 Influenza","enrollment":267},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT07494435","phase":"PHASE2","title":"Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Haichang Biotech Co., Ltd.","startDate":"2026-06-01","conditions":"Hepato Cellular Carcinoma (HCC), Renal Cell Cancer","enrollment":230},{"nctId":"NCT07498647","phase":"PHASE2","title":"Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia","status":"NOT_YET_RECRUITING","sponsor":"BioRay Pharmaceutical Co., Ltd.","startDate":"2026-04-01","conditions":"Gout and Hyperuricemia","enrollment":160},{"nctId":"NCT00268385","phase":"PHASE1","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-12-16","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma","enrollment":83},{"nctId":"NCT05593497","phase":"PHASE2","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-31","conditions":"High-Risk Prostate Cancer","enrollment":30},{"nctId":"NCT05941520","phase":"PHASE2","title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-23","conditions":"Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ","enrollment":80},{"nctId":"NCT05718375","phase":"PHASE2","title":"Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria","status":"COMPLETED","sponsor":"Curacle Co., Ltd.","startDate":"2023-02-14","conditions":"Diabetic Nephropathies","enrollment":240},{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":24},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT05855824","phase":"NA","title":"Toddler Biomarker of Nutrition Study","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-06-01","conditions":"Pediatric Nutrition, Nutrition, Healthy","enrollment":150},{"nctId":"NCT01038778","phase":"PHASE1, PHASE2","title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-29","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":47},{"nctId":"NCT07495254","phase":"NA","title":"Effectiveness of Combined Super Inductive System (SIS) Therapy With Therapeutic Exercise and Health Education in Lateral Elbow Tendinopathy","status":"NOT_YET_RECRUITING","sponsor":"University of Vic - Central University of Catalonia","startDate":"2026-03-30","conditions":"Lateral Epicondylitis (Tennis Elbow), Lateral Epicondylalgia, Lateral Elbow Tendinopathy","enrollment":224},{"nctId":"NCT07222488","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-09","conditions":"Bladder Cancer, Urinary Bladder Neoplasms","enrollment":45},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT03605550","phase":"PHASE1","title":"A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2018-08-01","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma","enrollment":64},{"nctId":"NCT07494084","phase":"PHASE4","title":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","status":"NOT_YET_RECRUITING","sponsor":"Washington State University","startDate":"2026-05-01","conditions":"Shift Work Schedule, Circadian Rhythm, Insulin Resistance","enrollment":24},{"nctId":"NCT07211828","phase":"NA","title":"EEG and Pain Monitor Data Under Anesthesia to Study Pharmacodynamic Effects of Opioids and Sedatives","status":"RECRUITING","sponsor":"Chi Kwan Fung","startDate":"2025-10-10","conditions":"Sedation and Analgesia, Cholangiopancreatography, Endoscopic Retrograde, Anesthesia, General","enrollment":20},{"nctId":"NCT06052267","phase":"PHASE3","title":"A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-08-30","conditions":"Asthma","enrollment":2700},{"nctId":"NCT07494149","phase":"NA","title":"Group-Based Exercise Intervention to Prevent Cognitive and Motor Decline","status":"RECRUITING","sponsor":"University of Bergamo","startDate":"2026-02-01","conditions":"Healthy, Older Adults","enrollment":158},{"nctId":"NCT07371650","phase":"PHASE2","title":"This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Traws Pharma, Inc.","startDate":"2025-12-15","conditions":"Influenza","enrollment":105},{"nctId":"NCT06745921","phase":"PHASE1","title":"Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-02-24","conditions":"West Nile Viral Infection","enrollment":30},{"nctId":"NCT06744504","phase":"PHASE3","title":"Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-10","conditions":"AML, RUNX1-RUNX1T1 Fusion Protein Expression","enrollment":300},{"nctId":"NCT06858579","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","status":"RECRUITING","sponsor":"Dianthus Therapeutics","startDate":"2025-02-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":480},{"nctId":"NCT07276360","phase":"PHASE2","title":"Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda","status":"RECRUITING","sponsor":"Uganda Cancer Institute","startDate":"2026-03-11","conditions":"Cervical Cancer, Cervix Cancer, Cervical Adenocarcinoma","enrollment":278},{"nctId":"NCT02830724","phase":"PHASE1, PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-06","conditions":"Pancreatic Cancer, Renal Cell Cancer, Breast Cancer","enrollment":124},{"nctId":"NCT02506153","phase":"PHASE3","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-10","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma","enrollment":1301},{"nctId":"NCT06321198","phase":"NA","title":"A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-02-10","conditions":"Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)","enrollment":12},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT05826509","phase":"PHASE2","title":"SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2023-08-10","conditions":"Prostate Cancer","enrollment":240},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT07169617","phase":"PHASE2","title":"Testing the SurVaxM Vaccine for Lung Cancer Prevention","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-02-25","conditions":"Lung Carcinoma","enrollment":80},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT07287670","phase":"PHASE2","title":"EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)","status":"NOT_YET_RECRUITING","sponsor":"Mediar Therapeutics","startDate":"2026-02","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":85},{"nctId":"NCT06980428","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-27","conditions":"Healthy Participants, Dyslipidemia","enrollment":136},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT07133633","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-09-26","conditions":"Radiographic Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT05145647","phase":"NA","title":"To Observe the Benefit of Adding Brachytherapy After CCRT on Resectable Esophageal Cancer Patients Without Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2022-03-30","conditions":"Esophageal Cancer","enrollment":18},{"nctId":"NCT07332091","phase":"PHASE2","title":"Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2026-01-22","conditions":"Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis","enrollment":84},{"nctId":"NCT06953323","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","startDate":"2025-07-10","conditions":"Advanced Solid Tumor","enrollment":86},{"nctId":"NCT07496567","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-04-30","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT06921317","phase":"PHASE1, PHASE2","title":"GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma","status":"RECRUITING","sponsor":"IVIEW Therapeutics Inc.","startDate":"2025-11-19","conditions":"Primary Open-Angle Glaucoma (POAG)","enrollment":12},{"nctId":"NCT05454566","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.","status":"NOT_YET_RECRUITING","sponsor":"ICM Co. Ltd.","startDate":"2026-11-15","conditions":"Osteoarthritis, Knee","enrollment":18},{"nctId":"NCT07296094","phase":"PHASE2","title":"Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-05-01","conditions":"Alcohol Use Disorder","enrollment":36},{"nctId":"NCT06742723","phase":"PHASE3","title":"A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-03","conditions":"Chronic Kidney Disease and Hypertension","enrollment":5000},{"nctId":"NCT05552469","phase":"PHASE1","title":"Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-08","conditions":"Myeloid Diseases","enrollment":62},{"nctId":"NCT07497438","phase":"PHASE3","title":"Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":176},{"nctId":"NCT05012033","phase":"","title":"Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2023-04-12","conditions":"Thyroid Eye Disease, Vasculitis, COPD Exacerbation Acute","enrollment":120},{"nctId":"NCT06568484","phase":"PHASE2, PHASE3","title":"Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-07","conditions":"Tuberculosis, Latent","enrollment":2530},{"nctId":"NCT04864314","phase":"NA","title":"Assessment of TetraSOD® Efficacy to Improve Semen Parameters in Men With Idiopathic Infertility","status":"COMPLETED","sponsor":"Fitoplancton Marino, S.L.","startDate":"2021-05-12","conditions":"Infertility, Male","enrollment":80},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT06385119","phase":"PHASE1","title":"A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.","status":"COMPLETED","sponsor":"Fore Biotherapeutics","startDate":"2024-04-24","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT06195306","phase":"PHASE2","title":"Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-07-28","conditions":"Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ","enrollment":66},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT03604978","phase":"PHASE1, PHASE2","title":"Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-17","conditions":"Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma","enrollment":38},{"nctId":"NCT06031844","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-16","conditions":"Coronary Heart Disease","enrollment":24},{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":360},{"nctId":"NCT05531786","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-06","conditions":"Graft vs Host Disease","enrollment":50},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT05488067","phase":"PHASE4","title":"Atorvastatin Therapy on Xanthoma in Alagille Syndrome","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2022-03-22","conditions":"Alagille Syndrome, Atorvastatin, Xanthoma","enrollment":15},{"nctId":"NCT06778122","phase":"NA","title":"In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors","status":"RECRUITING","sponsor":"University College, London","startDate":"2026-01-23","conditions":"Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs","enrollment":10},{"nctId":"NCT07489885","phase":"PHASE2","title":"A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2026-05","conditions":"Psoriasis","enrollment":75},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT05766046","phase":"NA","title":"Lung Cancer Prevention Screening Programme in Italy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ugo Pastorino","startDate":"2022-09-17","conditions":"Lung Cancer, COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection, Cardiovascular Diseases","enrollment":7324},{"nctId":"NCT07497165","phase":"","title":"Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma","enrollment":48},{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT04660344","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-03","conditions":"Muscle-invasive Bladder Cancer","enrollment":761},{"nctId":"NCT05554406","phase":"PHASE2","title":"Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-25","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":335},{"nctId":"NCT05139056","phase":"PHASE1","title":"Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2023-05-02","conditions":"Currently Only Enrolling Glioblastoma Patients at First Recurrence","enrollment":36},{"nctId":"NCT04234113","phase":"PHASE1","title":"Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors","status":"TERMINATED","sponsor":"SOTIO Biotech AG","startDate":"2019-06-13","conditions":"Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer","enrollment":115},{"nctId":"NCT06939296","phase":"PHASE3","title":"A Research Study of VCT220 in Adult Chinese Participants With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2024-12-24","conditions":"Obesity, Overweight","enrollment":840},{"nctId":"NCT06235697","phase":"PHASE3","title":"Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-04-25","conditions":"Prostate Cancer","enrollment":710},{"nctId":"NCT06706375","phase":"NA","title":"Compared Reversed US-Guided Dorsal Penile Nerve Block (RUSDPNB) With DPNB in Circumcisions for Pediatric Patients","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2024-11-29","conditions":"Circumcision, Ultrasound, Opioid Consumption","enrollment":216},{"nctId":"NCT07282457","phase":"PHASE1, PHASE2","title":"Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)","status":"NOT_YET_RECRUITING","sponsor":"Zhongmou Therapeutics","startDate":"2026-02-25","conditions":"Retinitis Pigmentosa (RP)","enrollment":21},{"nctId":"NCT07498517","phase":"PHASE2","title":"Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT","status":"NOT_YET_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2026-02-28","conditions":"Thrombosis","enrollment":90},{"nctId":"NCT07498855","phase":"","title":"Robustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary Irradiation","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-10-01","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT05724875","phase":"NA","title":"FLASH Radiotherapy for Skin Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2023-06-22","conditions":"Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT04092270","phase":"PHASE1","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-07","conditions":"Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":54},{"nctId":"NCT04530383","phase":"PHASE2","title":"Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function","status":"NOT_YET_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2026-04-15","conditions":"Cystic Fibrosis-related Diabetes, Cystic Fibrosis","enrollment":30},{"nctId":"NCT04277637","phase":"PHASE1","title":"Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2020-03-24","conditions":"Mature B-Cell Malignancies","enrollment":437},{"nctId":"NCT02888743","phase":"PHASE2","title":"Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-14","conditions":"Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":110},{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT04236388","phase":"NA","title":"Short Term Ketone Supplementation and Cardiometabolic Health","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2020-10-02","conditions":"Cardiovascular Risk Factor","enrollment":11},{"nctId":"NCT04975698","phase":"PHASE2","title":"HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2021-10-25","conditions":"HIV Associated Lymphoma","enrollment":12},{"nctId":"NCT06567470","phase":"PHASE2","title":"A Study With CIT-013 in RA Patients","status":"RECRUITING","sponsor":"Citryll BV","startDate":"2025-07-29","conditions":"Rheumatoid Arthritis","enrollment":88},{"nctId":"NCT04574856","phase":"PHASE2","title":"Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-11-04","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT07492407","phase":"","title":"CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-04","conditions":"MZL","enrollment":131},{"nctId":"NCT06687837","phase":"PHASE1","title":"Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons","status":"RECRUITING","sponsor":"Jeffrey S. Schweitzer, MD, PhD","startDate":"2025-04-29","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT01743950","phase":"PHASE2","title":"A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2012-12-03","conditions":"Glioma","enrollment":49},{"nctId":"NCT04221204","phase":"PHASE1","title":"A Monotherapy in Subjects With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"3D Medicines (Beijing) Co., Ltd.","startDate":"2019-09-01","conditions":"Solid Tumor, Adult","enrollment":42},{"nctId":"NCT07371338","phase":"PHASE1","title":"Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients","status":"RECRUITING","sponsor":"Innopeutics Corporation","startDate":"2026-05-30","conditions":"Parkinson Disease, Parkinson's Disease","enrollment":6},{"nctId":"NCT07492121","phase":"PHASE2","title":"Screening for Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"University of Zurich","startDate":"2026-09","conditions":"Lung Cancer Stage IV, Melanoma Stage IV, Breast Cancer Metastatic","enrollment":180},{"nctId":"NCT07492446","phase":"NA","title":"Effects of Carnitine Supplementation on Exercise-Induced Muscle Damage: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Istanbul Sabahattin Zaim University","startDate":"2025-05-09","conditions":"Recovery Methods, Exercise and Recovery, Exercise Fatigue","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":42,"reaction":"HEADACHE"},{"count":29,"reaction":"FATIGUE"},{"count":28,"reaction":"DIARRHOEA"},{"count":28,"reaction":"DRUG INEFFECTIVE"},{"count":27,"reaction":"NAUSEA"},{"count":26,"reaction":"DIZZINESS"},{"count":26,"reaction":"OFF LABEL USE"},{"count":24,"reaction":"PNEUMONIA"},{"count":24,"reaction":"PRURITUS"},{"count":23,"reaction":"CONSTIPATION"}],"_approvalHistory":[],"publicationCount":135054,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["0.9% Saline 1.0 mL vaccination","Caffeine Citrate 40mg/kg/day"],"phase":"marketed","status":"active","brandName":"High-dose","genericName":"High-dose","companyName":"Medical University of Graz","companyId":"medical-university-of-graz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose treatment involves administering a higher-than-standard dose of a medication to achieve a specific therapeutic effect. Used for Various conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":9,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}